Sunitinib - Revision history

Michael at 19:57, 8 November 2018

2018-11-08T19:57:55Z

← Older revision		Revision as of 19:57, 8 November 2018
Line 1:		Line 1:
	'''Sunitinib''' (marketed with the brand name ''Sutent'') is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).		'''Sunitinib''' (marketed with the brand name ''Sutent'' by Pfizer) is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).

	In RCC acts on:<ref>{{Cite journal \| last1 = Toon \| first1 = CW. \| last2 = Hasovits \| first2 = C. \| last3 = Paik \| first3 = J. \| last4 = Field \| first4 = M. \| last5 = Chou \| first5 = A. \| last6 = Hugh \| first6 = TJ. \| last7 = Pavlakis \| first7 = N. \| last8 = Gill \| first8 = AJ. \| title = Skin rash, a kidney mass and a family mystery dating back to World War II. \| journal = Med J Aust \| volume = 201 \| issue = 1 \| pages = 58-60 \| month = Jul \| year = 2014 \| doi = \| PMID = 24999901 }}</ref>		In RCC acts on:<ref>{{Cite journal \| last1 = Toon \| first1 = CW. \| last2 = Hasovits \| first2 = C. \| last3 = Paik \| first3 = J. \| last4 = Field \| first4 = M. \| last5 = Chou \| first5 = A. \| last6 = Hugh \| first6 = TJ. \| last7 = Pavlakis \| first7 = N. \| last8 = Gill \| first8 = AJ. \| title = Skin rash, a kidney mass and a family mystery dating back to World War II. \| journal = Med J Aust \| volume = 201 \| issue = 1 \| pages = 58-60 \| month = Jul \| year = 2014 \| doi = \| PMID = 24999901 }}</ref>

Michael at 13:34, 9 August 2018

2018-08-09T13:34:32Z

← Older revision		Revision as of 13:34, 9 August 2018
Line 5:		Line 5:
	*PDGFbeta.		*PDGFbeta.

	==~~Use~~==		==Uses==
	*[[Gastrointestinal stromal tumour]], imatinib-resistant.<ref>{{Cite journal \| last1 = Mulet-Margalef \| first1 = N. \| last2 = Garcia-Del-Muro \| first2 = X. \| title = Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. \| journal = Onco Targets Ther \| volume = 9 \| issue = \| pages = 7573-7582 \| month = \| year = 2016 \| doi = 10.2147/OTT.S101385 \| PMID = 28008275 }}</ref>		*[[Gastrointestinal stromal tumour]], imatinib-resistant.<ref>{{Cite journal \| last1 = Mulet-Margalef \| first1 = N. \| last2 = Garcia-Del-Muro \| first2 = X. \| title = Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. \| journal = Onco Targets Ther \| volume = 9 \| issue = \| pages = 7573-7582 \| month = \| year = 2016 \| doi = 10.2147/OTT.S101385 \| PMID = 28008275 }}</ref>
	*[[Renal cell carcinoma]] - especially [[clear cell renal cell carcinoma]].<ref name=pmid25075067>{{Cite journal \| last1 = Yildiz \| first1 = I. \| last2 = Ekenel \| first2 = M. \| last3 = Akman \| first3 = T. \| last4 = Kocar \| first4 = M. \| last5 = Uysal \| first5 = M. \| last6 = Kanitez \| first6 = M. \| last7 = Varol \| first7 = U. \| last8 = Bayoglu \| first8 = IV. \| last9 = Tural \| first9 = D. \| title = Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. \| journal = Anticancer Res \| volume = 34 \| issue = 8 \| pages = 4329-34 \| month = Aug \| year = 2014 \| doi = \| PMID = 25075067 }}</ref>		*[[Renal cell carcinoma]] - especially [[clear cell renal cell carcinoma]].<ref name=pmid25075067>{{Cite journal \| last1 = Yildiz \| first1 = I. \| last2 = Ekenel \| first2 = M. \| last3 = Akman \| first3 = T. \| last4 = Kocar \| first4 = M. \| last5 = Uysal \| first5 = M. \| last6 = Kanitez \| first6 = M. \| last7 = Varol \| first7 = U. \| last8 = Bayoglu \| first8 = IV. \| last9 = Tural \| first9 = D. \| title = Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. \| journal = Anticancer Res \| volume = 34 \| issue = 8 \| pages = 4329-34 \| month = Aug \| year = 2014 \| doi = \| PMID = 25075067 }}</ref>

Michael at 13:34, 9 August 2018

2018-08-09T13:34:18Z

← Older revision		Revision as of 13:34, 9 August 2018
Line 5:		Line 5:
	*PDGFbeta.		*PDGFbeta.

			==Use==
			*[[Gastrointestinal stromal tumour]], imatinib-resistant.<ref>{{Cite journal \| last1 = Mulet-Margalef \| first1 = N. \| last2 = Garcia-Del-Muro \| first2 = X. \| title = Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives. \| journal = Onco Targets Ther \| volume = 9 \| issue = \| pages = 7573-7582 \| month = \| year = 2016 \| doi = 10.2147/OTT.S101385 \| PMID = 28008275 }}</ref>
			*[[Renal cell carcinoma]] - especially [[clear cell renal cell carcinoma]].<ref name=pmid25075067>{{Cite journal \| last1 = Yildiz \| first1 = I. \| last2 = Ekenel \| first2 = M. \| last3 = Akman \| first3 = T. \| last4 = Kocar \| first4 = M. \| last5 = Uysal \| first5 = M. \| last6 = Kanitez \| first6 = M. \| last7 = Varol \| first7 = U. \| last8 = Bayoglu \| first8 = IV. \| last9 = Tural \| first9 = D. \| title = Sunitinib for patients with metastatic non-clear cell renal cell carcinoma: a Multicenter Retrospective Turkish Oncology Group trial. \| journal = Anticancer Res \| volume = 34 \| issue = 8 \| pages = 4329-34 \| month = Aug \| year = 2014 \| doi = \| PMID = 25075067 }}</ref>
	==See also==		==See also==
	*[[Tyrosine kinase inhibitors]].		*[[Tyrosine kinase inhibitors]].

Michael at 14:49, 30 May 2016

2016-05-30T14:49:43Z

← Older revision		Revision as of 14:49, 30 May 2016
Line 11:		Line 11:
	{{Reflist\|1}}		{{Reflist\|1}}

	[[Category: Clinical]]		[[Category:Clinical]]
			[[Category:Drugs]]

Michael at 15:07, 20 October 2014

2014-10-20T15:07:34Z

← Older revision		Revision as of 15:07, 20 October 2014
Line 1:		Line 1:
	'''Sunitinib''' is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).		'''Sunitinib''' (marketed with the brand name ''Sutent'') is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).

	In RCC acts on:<ref>{{Cite journal \| last1 = Toon \| first1 = CW. \| last2 = Hasovits \| first2 = C. \| last3 = Paik \| first3 = J. \| last4 = Field \| first4 = M. \| last5 = Chou \| first5 = A. \| last6 = Hugh \| first6 = TJ. \| last7 = Pavlakis \| first7 = N. \| last8 = Gill \| first8 = AJ. \| title = Skin rash, a kidney mass and a family mystery dating back to World War II. \| journal = Med J Aust \| volume = 201 \| issue = 1 \| pages = 58-60 \| month = Jul \| year = 2014 \| doi = \| PMID = 24999901 }}</ref>		In RCC acts on:<ref>{{Cite journal \| last1 = Toon \| first1 = CW. \| last2 = Hasovits \| first2 = C. \| last3 = Paik \| first3 = J. \| last4 = Field \| first4 = M. \| last5 = Chou \| first5 = A. \| last6 = Hugh \| first6 = TJ. \| last7 = Pavlakis \| first7 = N. \| last8 = Gill \| first8 = AJ. \| title = Skin rash, a kidney mass and a family mystery dating back to World War II. \| journal = Med J Aust \| volume = 201 \| issue = 1 \| pages = 58-60 \| month = Jul \| year = 2014 \| doi = \| PMID = 24999901 }}</ref>
Line 10:		Line 10:
	==References==		==References==
	{{Reflist\|1}}		{{Reflist\|1}}

			[[Category: Clinical]]

Michael: create

2014-10-20T15:06:35Z

create

New page

'''Sunitinib''' is a [[tyrosine kinase inhibitor]] used to treat [[renal cell carcinoma]] (RCC).

In RCC acts on:<ref>{{Cite journal | last1 = Toon | first1 = CW. | last2 = Hasovits | first2 = C. | last3 = Paik | first3 = J. | last4 = Field | first4 = M. | last5 = Chou | first5 = A. | last6 = Hugh | first6 = TJ. | last7 = Pavlakis | first7 = N. | last8 = Gill | first8 = AJ. | title = Skin rash, a kidney mass and a family mystery dating back to World War II. | journal = Med J Aust | volume = 201 | issue = 1 | pages = 58-60 | month = Jul | year = 2014 | doi = | PMID = 24999901 }}</ref>
*VEGF.
*PDGFbeta.

==See also==
*[[Tyrosine kinase inhibitors]].

==References==
{{Reflist|1}}